29.08.2017 17:45:00

DIMENSION THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dimension Therapeutics, Inc.

NEW ORLEANS, Aug. 28, 2017 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Dimension Therapeutics, Inc. ("Dimension" or the "Company") (NASDAQ: DMTX) to REGENXBIO Inc. (NASDAQ: RGNX). Under the terms of the proposed transaction, shareholders of Dimension will receive only 0.1573 shares of REGENXBIO for each share of Dimension that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Kahn Swick & Foti, LLC (

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC
206 Covington St.
Madisonville, LA 70447

 

View original content with multimedia:http://www.prnewswire.com/news-releases/dimension-therapeutics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick--foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-dimension-therapeutics-inc-300510889.html

SOURCE Kahn Swick & Foti, LLC

Nachrichten zu Dimension Therapeutics Incmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Dimension Therapeutics Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

REGENXBIO Inc 8,00 0,63% REGENXBIO Inc